Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.41 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12789821 | 0.88 | GRN (0.43) | PTGS2PTGS1CACNA1HKCNH2 | |
| SCHEMBL14129178 | 0.87 | PTGS1 (0.59) | PTGS2PTGS1NR3C2 | |
| SCHEMBL30677078 | 0.85 | PTGS1 (0.43) | PTGS2PTGS1KCNH2CRACR2A | |
| SCHEMBL30677118 | 0.82 | PDPK1 (0.50) | PTGS2PTGS1CRACR2A | |
| SCHEMBL30443569 | 0.82 | KLKB1 (0.49) | PTGS2PTGS1 | |
| SCHEMBL31546298 | 0.80 | PDPK1 (0.41) | PTGS2PTGS1CRACR2A | |
| SCHEMBL18163944 | 0.79 | PTGS2 (0.55) | PTGS2PTGS1KCNH2 | |
| SCHEMBL18161148 | 0.79 | PPARA (0.47) | CACNA1HKCNH2 | |
| SCHEMBL25511207 | 0.78 | PTGS1 (0.46) | PTGS2PTGS1 | |
| SCHEMBL25511208 | 0.78 | PTGS1 (0.46) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392350-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3080087-B1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20180222867-A1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION | 2018-08-09 | — | — | US | disclosed |
| US-9914706-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392350-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | ATP5F1A, ATP5ME, ATP5F1D | PTGS2 768/4885PTGS1 425/4885CACNA1H 3855/4885 |
| US-20180222867-A1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | PTGS2 768/4885PTGS1 425/4885CACNA1H 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.